Silent (clinically nonfunctioning) pituitary adenomas
详细信息 查看全文
- 作者：Sarah E. Mayson (1) (2)
Peter J. Snyder (1) - 关键词：Pituitary adenomas ; Silent pituitary adenomas ; Clinically silent pituitary adenomas ; Totally silent pituitary adenomas ; Silent somatotroph adenomas ; Silent corticotroph adenomas
- 刊名：Journal of Neuro-Oncology
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：117
- 期：3
- 页码：429-436
- 全文大小：
- 参考文献：1. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72(3):377-82. doi:10.1111/j.1365-2265.2009.03667.x CrossRef
2. Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992-007. J Clin Endocrinol Metab 95(9):4268-275. doi:10.1210/jc.2010-0537 CrossRef
3. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10?years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203-16. doi:10.1530/eje.1.02326 CrossRef
4. Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ (2011) Clinically silent somatotroph adenomas are common. Eur J Endocrinol 165(1):39-4. doi:10.1530/EJE-11-0216 CrossRef
5. Ho DM, Hsu CY, Ting LT, Chiang H (1997) The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Hum Pathol 28(8):905-11 CrossRef
6. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3):580-84. doi:10.1227/01.NEU.0000290906.53685.79 discussion 584-585 CrossRef
7. Wang EL, Qian ZR, Yamada S, Rahman MM, Inosita N, Kageji T, Endo H, Kudo E, Sano T (2009) Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20(4):209-20. doi:10.1007/s12022-009-9094-y CrossRef
8. Clarke MJ, Erickson D, Castro MR, Atkinson JL (2008) Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 109(1):17-2. doi:10.3171/JNS/2008/109/7/0017 CrossRef
9. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290-295. doi:10.1210/jc.2005-0998 CrossRef
10. Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96-02. doi:10.1111/j.1365-2265.2011.04163.x CrossRef
11. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotroph adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98(3):617-36
12. Baldeweg SE, Pollock JR, Powell M, Ahlquist J (2005) A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 19(1):38-2. doi:10.1080/02688690500081230 CrossRef
13. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY (2010) Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol 72(5):648-53. doi:10.1111/j.1365-2265.2009.03673.x CrossRef
14. Bradley KJ, Wass JA, Turner HE (2003) Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol 58(1):59-4 CrossRef
15. Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, Pileggi AV, Oyesiku NM (2012) Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery 71(2):296-03. doi:10.1227/NEU.0b013e318257c1f0 discussion 304 CrossRef
16. Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol 71(1):92-9. doi:10.1111/j.1365-2265.2008.03514.x CrossRef
17. Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG (2006) Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155(6):823-29. doi:10.1530/eje.1.02298 CrossRef
18. Nomikos P, Ladar C, Fahlbusch R, Buchfelder M (2004) Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas: a study on 721 patients. Acta Neurochir (Wien) 146(1):27-5. doi:10.1007/s00701-003-0174-3 CrossRef
19. Chen L, White WL, Spetzler RF, Xu B (2011) A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. J Neurooncol 102(1):129-38. doi:10.1007/s11060-010-0302-x CrossRef
20. Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA (2007) What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol 67(6):938-43. doi:10.1111/j.1365-2265.2007.02990.x CrossRef
21. Ambrosi B, Colombo P, Bochicchio D, Bassetti M, Masini B, Faglia G (1992) The silent corticotropinoma: is clinical diagnosis possible? J Endocrinol Invest 15(6):443-52 CrossRef
22. Salgado LR, Machado MC, Cukiert A, Liberman B, Kanamura CT, Alves VA (2006) Cushing’s disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol 17(2):191-99 CrossRef
23. Melcescu E, Gannon AW, Parent AD, Fratkin JF, Nicholas WC, Koch CA, Galhom A (2013) Silent or subclinical corticotroph pituitary macroadenoma transforming into Cushing disease: 11-year follow-up. Neurosurgery 72(1):E144–E146. doi:10.1227/NEU.0b013e3182750850 CrossRef
24. Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R (2009) Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 12(1):80-6. doi:10.1007/s11102-008-0085-7 CrossRef
25. Oppenheim DS, Kana AR, Sangha JS, Klibanski A (1990) Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: clinically nonfunctioning and somatotroph adenomas. J Clin Endocrinol Metab 70(4):859-64 CrossRef
26. Snyder PJ (1985) Gonadotroph cell adenomas of the pituitary. Endocr Rev 6(4):552-63 CrossRef
27. Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, Snyder PJ (1993) Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 77(5):1352-355
28. Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, Snyder PJ (1991) Recognition of gonadotroph adenomas in women. N Engl J Med 324(9):589-94. doi:10.1056/NEJM199102283240904 CrossRef
29. Castelbaum AJ, Bigdeli H, Post KD, Freedman MF, Snyder PJ (2002) Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril 78(6):1311-313 CrossRef
30. Djerassi A, Coutifaris C, West VA, Asa SL, Kapoor SC, Pavlou SN, Snyder PJ (1995) Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 80(2):591-94
31. Lopez JA, Kleinschmidt-Demasters Bk B, Sze CI, Woodmansee WW, Lillehei KO (2004) Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol 35(9):1137-147 CrossRef
32. Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA, Pereira AM (2007) The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 156(2):217-24. doi:10.1530/eje.1.02334 CrossRef
33. Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y (2003) A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 149(2):123-27 CrossRef
34. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525-32. doi:10.3171/JNS/2008/108/3/0525 CrossRef
35. Murad MH, Fernandez-Balsells MM, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Perez L, Ponce de Leon-Lovaton PG, Albuquerque FN, Carey J, Erwin PJ, Montori VM (2010) Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol 73(6):777-91. doi:10.1111/j.1365-2265.2010.03875.x CrossRef
36. Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71-3. doi:10.1007/s11102-011-0347-7 CrossRef
37. Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333-42. doi:10.1159/000339823 CrossRef
38. O’Sullivan EP, Woods C, Glynn N, Behan LA, Crowley R, O’Kelly P, Smith D, Thompson CJ, Agha A (2009) The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin Endocrinol 71(5):709-14. doi:10.1111/j.1365-2265.2009.03583.x CrossRef
39. Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96(7):1992-003. doi:10.1210/jc.2011-0251 CrossRef
40. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163(2):193-00. doi:10.1530/EJE-10-0255 CrossRef
41. Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, Stewart PM (1998) Radiotherapy for non-function pituitary tumours. Clin Endocrinol 48(3):331-37 CrossRef
42. Park KJ, Kano H, Parry PV, Niranjan A, Flickinger JC, Lunsford LD, Kondziolka D (2011) Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery 69(6):1188-199. doi:10.1227/NEU.0b013e318222afed CrossRef
43. Gopalan R, Schlesinger D, Vance ML, Laws E, Sheehan J (2011) Long-term outcomes after Gamma knife radiosurgery for patients with a nonfunctioning pituitary adenoma. Neurosurgery 69(2):284-93. doi:10.1227/NEU.0b013e31821bc44e CrossRef
44. Dekkers OM, Pereira AM, Romijn JA (2008) Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 93(10):3717-726. doi:10.1210/jc.2008-0643 CrossRef
45. Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ (1994) Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 30(3):557-65 CrossRef
46. Erridge SC, Conkey DS, Stockton D, Strachan MW, Statham PF, Whittle IR, Grant R, Kerr GR, Gregor A (2009) Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 93(3):597-01. doi:10.1016/j.radonc.2009.09.011 CrossRef
47. Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC (2013) Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 16(1):91-00. doi:10.1007/s11102-012-0380-1 CrossRef
48. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89(4):1674-683 CrossRef
49. Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, Paschke R (2001) Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4(3):173-78 CrossRef
50. Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16(2):189-94. doi:10.1007/s11102-012-0403-y CrossRef
51. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223-30. doi:10.1210/jc.2008-1533 CrossRef
52. Petrossians P, Ronci N, Valdes Socin H, Kalife A, Stevenaert A, Bloch B, Tabarin A, Beckers A (2001) ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144(1):51-7 CrossRef
53. Fusco A, Giampietro A, Bianchi A, Cimino V, Lugli F, Piacentini S, Lorusso M, Tofani A, Perotti G, Lauriola L, Anile C, Maira G, Pontecorvi A, De Marinis L (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4):571-78. doi:10.1007/s11102-011-0370-8 CrossRef
54. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A (2003) Immunohistochemical detection of somatostatin receptor subtypes in “clinically nonfunctioning-pituitary adenomas. Endocr Pathol 14(3):231-38
55. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156(1):65-4. doi:10.1530/eje.1.02313 CrossRef - 作者单位：Sarah E. Mayson (1) (2)
Peter J. Snyder (1)
1. Division of Endocrinology Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
2. Division of Endocrinology, The Warren Alpert Medical School of Brown University, Providence, RI, 02903, USA - ISSN：1573-7373
文摘
Silent, or clinically nonfunctioning, pituitary adenomas can arise from any anterior pituitary cell type. Some are “clinically silent-in that they result in a supranormal serum concentration of the hormonal product of the cell type from which the adenoma arose but do not cause the clinical manifestations typical of excessive levels of that hormone. Others are “totally silent-in that they result in neither hormonal excess nor clinical manifestations. Gonadotroph and null cell adenomas are the most prevalent types and are typically silent. Somatotroph and corticotroph adenomas typically cause clinical syndromes but occasionally are clinically or totally silent. Those that are silent are usually larger and grow more aggressively than those that cause clinical syndromes. Silent adenomas are usually not discovered until they become very large and cause neurologic defects, such as visual impairment, but are also often discovered incidentally when neuroimaging is performed for another reason. Silent adenomas may become, rarely, clinically apparent over time. The diagnosis of a silent pituitary adenoma begins with the detection of a sellar mass by MRI. Biochemical testing can identify the adenoma cell type in those that are clinically silent. Silent adenomas that cause neurologic deficits require transsphenoidal surgery, but those that do not can be followed by MRI. Residual or recurrent disease is treated by radiation therapy, which is usually effective in preventing further growth but results in hormonal deficiencies in about half of patients. Dopamine agonists and somatostatin analogs are usually ineffective, but occasionally have been associated with reduced adenoma size.